Fig. 1
From: Anti-amyloid therapies for Alzheimer disease: finally, good news for patients
The relative safety and efficacy of putative amyloid-β-lowering therapies in patients with sporadic early-symptomatic Alzheimer disease. The efficacy and safety of selected amyloid-lowering therapies are depicted via scatter plot, referencing available data from Phase 3 clinical trials completed after 2016. Monoclonal antibodies accessible in the US under accelerated approval are depicted in red (donanemab remains under consideration). Other monoclonal antibodies are depicted in black. Agents with other mechanisms of action are depicted in gray. Dashed lines depict clinical meaningfulness. Agents in the top right quadrant met established endpoints for efficacy and safety. For more information consult clinicaltrials.gov, donanemab NCT04437511 [2] lecanemab NCT003887455 [1]; aducanumab NCT02477800, NCT02484547 [5]; gantenerumab NCT02051608, NCT01224106; solanezumab NCT01900665; crenezumab NCT03114657, NCT02670083; elenbecestat NCT012956486; lanabecestat NCT02972658, NCT02245737, NCT02783573; verubecestat NCT01953601